Welcome to our dedicated page for Rapport Therapeutics SEC filings (Ticker: RAPP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Rapport Therapeutics, Inc. (Nasdaq: RAPP) provides access to the company’s official regulatory disclosures as a clinical-stage biotechnology issuer. Rapport’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on The Nasdaq Global Market under the symbol RAPP, so its filings offer detailed information on its precision neuroscience business and capital markets activity.
Through this page, readers can review Form 10-K and Form 10-Q reports (when filed) for discussions of Rapport’s RAP technology platform, the development of RAP-219 for drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain, and additional programs in chronic pain, migraine, and hearing or vestibular disorders. These periodic reports also describe risk factors, research and development expenses, and other elements of the company’s operating profile.
Frequent Form 8-K filings from RAPP document material events such as positive Phase 2a trial results for RAP-219 in focal onset seizures, new data analyses presented at scientific meetings, public offerings of common stock under an effective shelf registration statement on Form S-3, and quarterly financial results and business updates. Some 8-Ks also summarize regulatory developments, including clinical holds, end-of-Phase 2 planning, and changes to at-the-market sales arrangements.
Investors can also use this page to locate information related to shareholder meetings and voting outcomes, as disclosed in 8-K items covering submissions of matters to a vote of security holders. Insider transaction reports on Form 4, when available, complement these filings by showing equity activity by directors and officers.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, highlight clinical and financial milestones, and make it easier to understand how new disclosures may relate to Rapport’s RAP-219 program and broader precision neuroscience pipeline. Real-time updates from EDGAR help ensure that new RAPP filings, including 10-K, 10-Q, 8-K, and Form 4 submissions, are quickly accessible in one place.
Rapport Therapeutics, Inc. registered up to $150,000,000 of common stock for sale pursuant to an at-the-market sales agreement to be used on a shelf registration, to be sold from time to time after effectiveness.
The prospectus covers issuances of common stock, preferred stock, debt securities, warrants and units; the shelf replaces a prior Form S-3 that will terminate on July 7, 2028. As of March 6, 2026, there were 47,799,985 shares of common stock outstanding and the closing price was $30.24 per share on The Nasdaq Global Market under the symbol RAPP.
Rapport Therapeutics filed its annual report describing a precision neuroscience pipeline built on receptor associated protein (RAP) biology. The company had 47,792,943 common shares outstanding as of March 2, 2026, and non-affiliate equity market value of $275,840,930 as of June 30, 2025.
Lead candidate RAP-219, a TARPγ8‑targeted AMPA receptor modulator, showed positive Phase 2a proof‑of‑concept results in drug‑resistant focal onset seizures, with 85.2% of patients achieving at least a 30% reduction in intracranial long episodes and 72.0% achieving at least a 50% reduction in clinical seizures over eight weeks.
The report outlines plans for two global Phase 3 trials in focal onset seizures starting in the second quarter of 2026, further development in primary generalized tonic‑clonic seizures and bipolar mania, a long‑acting injectable formulation, and α6β4 and α9α10 nicotinic acetylcholine receptor programs for chronic pain, migraine, and hearing or vestibular disorders.
Rapport Therapeutics reported larger losses for the fourth quarter and full year 2025 as it ramped investment in its precision neuroscience pipeline. Quarterly net loss was $33.8 million versus $20.0 million a year earlier, and full-year net loss rose to $111.5 million from $78.3 million, driven mainly by higher R&D spending.
R&D expenses reached $94.8 million in 2025, up from $60.9 million, while G&A expenses increased to $30.3 million from $22.1 million. The company ended 2025 with $490.5 million in cash, cash equivalents, and short-term investments and expects this to fund operations into the second half of 2029.
Lead candidate RAP‑219 showed strong Phase 2a results in focal onset seizures, with a 77.8% median seizure reduction, 72% of patients achieving at least 50% reduction, and 24% achieving seizure freedom over eight weeks. Rapport plans to start a Phase 3 program in focal onset seizures in the second quarter of 2026 and expand into primary generalized tonic‑clonic seizures with a Phase 3 trial in 2027.
The company also advanced a Phase 2 trial in bipolar mania, long-acting injectable development, and an α6β4 chronic pain program. A new collaboration with Tenacia Biotechnology grants Tenacia rights to RAP‑219 in Greater China, with Rapport eligible for a $20 million upfront payment, up to $308 million in potential milestones and other payments, and tiered royalties.
Rapport Therapeutics, Inc. Chief Operating Officer Cheryl Gault reported an open-market sale of 2,014 shares of common stock at a weighted average price of $28.93 per share. According to the filing, the shares were sold solely to satisfy taxes from the vesting of a previously granted restricted stock unit award and did not represent a discretionary trade. After this transaction, she directly holds 169,914 shares of common stock. The sales occurred in multiple trades at prices ranging from $28.34 to $28.94.
Morgan Stanley Smith Barney LLC filed a Form 144 reporting proposed sale of restricted stock units that vested under a registered compensation plan. The filing lists the securities as Common and the relevant date is 03/03/2026; the brokerage location shows New York, NY. The notice is for sale activity under Section 144 procedures.
Rapport Therapeutics Chief Executive Officer Abraham Ceesay reported open-market sales of a total of 10,916 shares of common stock on February 18 under pre-arranged Rule 10b5-1 trading plans. He sold 5,833 shares held directly, at weighted average prices of $29.0516 and $29.7983 per share. An additional 5,083 shares were sold by The Dorothy Ceesay Irrevocable Trust, also at weighted average prices around $29 per share, with Ceesay disclaiming beneficial ownership except for any pecuniary interest. After these transactions, he holds 556,247 shares directly, while trusts associated with him hold 20,729 and 81,729 shares, respectively.
Rapport Therapeutics Chief Scientific Officer David Bredt reported a mix of option exercises and share sales in company stock. On February 19, 2026, he exercised stock options for 6,000 shares at $1.80 per share, acquiring an equal number of common shares through a cash exercise.
Earlier, on February 17, 2026, he sold a total of 8,500 shares of common stock in open-market transactions at weighted average prices of $28.0211, $28.9497, and $29.5944, under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2024. Following these transactions, he directly holds 387,075 shares of common stock and 88,080 stock options.
Rapport Therapeutics, Inc. (RAPP) received an updated ownership report showing that funds managed by Cormorant Asset Management and Bihua Chen beneficially own 3,027,521 shares of common stock, representing 6.35% of the company. This percentage is based on 47,661,138 shares outstanding as of November 3, 2025, as reported in Rapport’s Form 10-Q. The filing states these shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Rapport Therapeutics reported that Chief Medical Officer Jeffrey Sevigny received a grant of stock options on February 2, 2026. The award covers 130,000 stock options to purchase common stock at an exercise price of $27.75 per share, expiring on February 2, 2036.
The options vest in 48 equal monthly installments starting after January 1, 2026, and require Dr. Sevigny’s continued service on each vesting date. After this grant, he beneficially owns 130,000 derivative securities directly.
Rapport Therapeutics CEO Abraham Ceesay received a new stock option grant covering 428,000 shares of common stock. The option has an exercise price of $27.75 per share and was awarded on February 2, 2026. It was reported as a direct holding.
The shares underlying this option vest in forty-eight equal monthly installments following January 1, 2026, conditioned on Ceesay’s continued service with the company on each vesting date. After this grant, he beneficially owned 428,000 derivative securities in the form of stock options.